XML 56 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Tables)
 12 Months Ended
Aug. 31, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Recognized Stock-based Compensation Expense
The Company recognized stock-based compensation expense within selling, general and administrative expense as follows (in millions):
  Fiscal Year Ended August 31,
  2022 2021 2020
Restricted stock units $ 67  $ 91  $ 74 
Employee stock purchase plan 14  11  9 
Total $ 81  $ 102  $ 83 
Schedule of Shares Available for Issuance
Following is a reconciliation of the shares available to be issued under the 2021 EIP as of August 31, 2022:
  Shares Available for Grant
Balance as of August 31, 2021 10,981,300 
Restricted stock units granted, net of forfeitures(1)
 (1,007,006)
Balance as of August 31, 2022 9,974,294 
 
(1)Represents the maximum number of shares that can be issued based on the achievement of certain performance criteria.
Schedule of Restricted Stock Activity The following table summarizes restricted stock units activity from August 31, 2021 through August 31, 2022:
Shares Weighted-
Average
Grant-Date
Fair Value
Outstanding as of August 31, 2021 5,909,131  $ 36.51 
Changes during the period
Shares granted(1)
 1,306,995  $ 68.11 
Shares vested (2,503,143) $ 28.66 
Shares forfeited (299,989) $ 42.90 
Outstanding as of August 31, 2022 4,412,994  $ 49.87 
(1)For those shares granted that are based on the achievement of certain performance criteria, the amount represents the maximum number of shares that can vest. During the fiscal year ended August 31, 2022, the Company awarded approximately 0.7 million time-based restricted stock units, 0.2 million performance-based restricted stock units and 0.2 million market-based restricted stock units based on target performance criteria.
Schedule of Share-based Compensation Information
The following table represents the restricted stock units and stock appreciation rights (“SARS”) stock-based compensation information for the periods indicated (in millions):
  Fiscal Year Ended August 31,
  2022 2021 2020
Intrinsic value of SARS exercised $ —  $ —  $ 2 
Fair value of restricted stock units vested $ 72  $ 69  $ 56 
Tax benefit for stock compensation expense(1)
 $ 2  $ 1  $ 1 
Unrecognized stock-based compensation expense — restricted stock units $ 34 
Remaining weighted-average period for restricted stock units expense 1.4 years
 
(1)Classified as income tax expense within the Consolidated Statements of Operations.
Schedule of Weighted Average Assumptions Used in Black-Scholes Option Pricing Model
The fair value of shares issued under the ESPP was estimated on the commencement date of each offering period using the Black-Scholes option pricing model. The following weighted-average assumptions were used in the model for each respective period:
  Fiscal Year Ended August 31,
  2022 2021 2020
Expected dividend yield 0.3  % 0.5  % 0.4  %
Risk-free interest rate 0.1  % 0.1  % 1.9  %
Expected volatility(1)
 29.6  % 32.9  % 30.7  %
Expected life 0.5 years 0.5 years 0.5 years
(1)The expected volatility was estimated using the historical volatility derived from the Company’s common stock.
Cash Dividends Declared to Common Stockholders The following table sets forth certain information relating to the Company’s cash dividends declared to common stockholders during fiscal years 2022 and 2021:
(in millions, except for per share data) Dividend
Declaration Date		 Dividend
per Share		 Total of Cash
Dividends
Declared		 Date of Record for
Dividend Payment		 Dividend Cash
Payment Date
Fiscal Year 2022: October 21, 2021 $ 0.08  $ 12  November 15, 2021 December 1, 2021
January 20, 2022 $ 0.08  $ 12  February 15, 2022 March 2, 2022
April 21, 2022 $ 0.08  $ 12  May 16, 2022 June 2, 2022
July 21, 2022 $ 0.08  $ 11  August 15, 2022 September 2, 2022
Fiscal Year 2021: October 15, 2020 $ 0.08  $ 12  November 16, 2020 December 2, 2020
January 21, 2021 $ 0.08  $ 12  February 15, 2021 March 2, 2021
April 22, 2021 $ 0.08  $ 12  May 14, 2021 June 2, 2021
July 22, 2021 $ 0.08  $ 12  August 13, 2021 September 2, 2021
Schedule of Common Stock Outstanding
The following represents the common stock outstanding for the fiscal year ended:
Fiscal Year Ended August 31,
2022 2021 2020
Common stock outstanding:
Beginning balances
 144,496,077  150,330,358  153,520,380 
Shares issued upon exercise of stock options
 —  9,321  56,999 
Shares issued under employee stock purchase plan
 970,480  1,288,397  1,106,852 
Vesting of restricted stock
 2,503,143  2,290,104  2,259,623 
Purchases of treasury stock under employee stock plans
 (713,667) (622,703) (621,250)
Treasury shares purchased(1)(2)
 (11,762,053) (8,799,400) (5,992,246)
Ending balances
 135,493,980  144,496,077  150,330,358 
 
(1)In July 2021, the Board of Directors approved an authorization for the repurchase of up to $1.0 billion of the Company’s common stock (the “2022 Share Repurchase Program”). As of August 31, 2022, 12.4 million shares had been repurchased for $737 million and $263 million remains available under the 2022 Share Repurchase Program.
(2)In September 2022, the Board of Directors approved an authorization for the repurchase of up to $1.0 billion of the Company’s common stock (the “2023 Share Repurchase Program”).